Guido Tricot
Concepts (548)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 147 | 2024 | 2998 | 9.120 |
Why?
| Hematopoietic Stem Cell Transplantation | 28 | 2024 | 578 | 3.650 |
Why?
| Pyrazines | 20 | 2023 | 188 | 2.670 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 35 | 2024 | 1000 | 2.520 |
Why?
| Boronic Acids | 19 | 2014 | 183 | 2.470 |
Why?
| Thalidomide | 28 | 2023 | 378 | 2.440 |
Why?
| Antineoplastic Agents | 30 | 2020 | 1172 | 1.970 |
Why?
| Transplantation, Autologous | 30 | 2024 | 481 | 1.960 |
Why?
| Transplantation Conditioning | 9 | 2019 | 87 | 1.480 |
Why?
| Drug Resistance, Neoplasm | 17 | 2020 | 316 | 1.480 |
Why?
| Paraproteinemias | 8 | 2018 | 72 | 1.290 |
Why?
| Humans | 157 | 2024 | 50503 | 1.200 |
Why?
| Neoplastic Stem Cells | 5 | 2020 | 98 | 1.190 |
Why?
| Protease Inhibitors | 6 | 2011 | 58 | 1.080 |
Why?
| Venous Thrombosis | 7 | 2009 | 87 | 1.050 |
Why?
| Melphalan | 16 | 2023 | 178 | 1.010 |
Why?
| Stem Cell Transplantation | 13 | 2023 | 179 | 1.000 |
Why?
| Angiogenesis Inhibitors | 9 | 2009 | 183 | 1.000 |
Why?
| Aged | 58 | 2024 | 9741 | 0.950 |
Why?
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 833 | 0.940 |
Why?
| Hematopoietic Stem Cell Mobilization | 5 | 2014 | 58 | 0.940 |
Why?
| Prognosis | 33 | 2024 | 1978 | 0.930 |
Why?
| Middle Aged | 60 | 2024 | 12611 | 0.890 |
Why?
| Alkaline Phosphatase | 5 | 2011 | 93 | 0.850 |
Why?
| Busulfan | 3 | 2019 | 19 | 0.850 |
Why?
| Treatment Outcome | 39 | 2022 | 5283 | 0.790 |
Why?
| Plasma Cells | 11 | 2023 | 221 | 0.780 |
Why?
| Dexamethasone | 16 | 2024 | 432 | 0.750 |
Why?
| Male | 68 | 2024 | 25907 | 0.700 |
Why?
| Chromosome Aberrations | 9 | 2008 | 280 | 0.670 |
Why?
| Female | 64 | 2024 | 27081 | 0.660 |
Why?
| Thromboembolism | 3 | 2009 | 55 | 0.660 |
Why?
| Neoplasm Proteins | 6 | 2021 | 320 | 0.630 |
Why?
| Chromosomes, Human, Pair 13 | 6 | 2008 | 34 | 0.610 |
Why?
| Disease-Free Survival | 14 | 2019 | 444 | 0.580 |
Why?
| Immunoglobulin Light Chains | 3 | 2016 | 84 | 0.570 |
Why?
| Survival Rate | 18 | 2019 | 909 | 0.570 |
Why?
| Bone Remodeling | 2 | 2010 | 149 | 0.560 |
Why?
| Anticoagulants | 5 | 2009 | 256 | 0.560 |
Why?
| Gene Expression Profiling | 18 | 2023 | 1025 | 0.560 |
Why?
| Blood Transfusion | 1 | 2018 | 129 | 0.550 |
Why?
| Immunologic Factors | 5 | 2012 | 111 | 0.550 |
Why?
| Cell Line, Tumor | 18 | 2023 | 1398 | 0.530 |
Why?
| Follow-Up Studies | 21 | 2024 | 2242 | 0.520 |
Why?
| Receptors, Retinoic Acid | 2 | 2013 | 22 | 0.510 |
Why?
| Antineoplastic Agents, Alkylating | 7 | 2008 | 73 | 0.510 |
Why?
| Proteasome Inhibitors | 6 | 2018 | 104 | 0.500 |
Why?
| IMP Dehydrogenase | 2 | 2006 | 3 | 0.500 |
Why?
| Mycophenolic Acid | 2 | 2006 | 18 | 0.500 |
Why?
| Clinical Trials as Topic | 9 | 2022 | 486 | 0.490 |
Why?
| Adult | 38 | 2024 | 13577 | 0.490 |
Why?
| Combined Modality Therapy | 13 | 2008 | 641 | 0.480 |
Why?
| Cell Proliferation | 15 | 2020 | 985 | 0.470 |
Why?
| Recurrence | 16 | 2018 | 659 | 0.470 |
Why?
| Antigens, Neoplasm | 5 | 2007 | 148 | 0.460 |
Why?
| Up-Regulation | 5 | 2020 | 446 | 0.460 |
Why?
| Apoptosis | 9 | 2019 | 1097 | 0.460 |
Why?
| Antibodies, Monoclonal | 3 | 2015 | 462 | 0.450 |
Why?
| Animals | 30 | 2024 | 13124 | 0.450 |
Why?
| Osteogenesis | 3 | 2012 | 356 | 0.440 |
Why?
| Retrospective Studies | 18 | 2024 | 6263 | 0.440 |
Why?
| Venous Thromboembolism | 3 | 2011 | 74 | 0.440 |
Why?
| Survival Analysis | 12 | 2021 | 661 | 0.430 |
Why?
| Disease Progression | 12 | 2019 | 829 | 0.430 |
Why?
| Signal Transduction | 12 | 2020 | 1624 | 0.430 |
Why?
| Doxorubicin | 8 | 2018 | 236 | 0.430 |
Why?
| Bone Diseases | 3 | 2012 | 96 | 0.420 |
Why?
| Neoplasms, Second Primary | 2 | 2024 | 74 | 0.410 |
Why?
| Thrombosis | 4 | 2012 | 250 | 0.400 |
Why?
| Central Nervous System Neoplasms | 2 | 2004 | 63 | 0.400 |
Why?
| T-Lymphocytes | 10 | 2024 | 325 | 0.400 |
Why?
| Myeloablative Agonists | 5 | 2014 | 32 | 0.390 |
Why?
| Bone Marrow | 7 | 2022 | 363 | 0.390 |
Why?
| Transplantation, Homologous | 6 | 2004 | 145 | 0.380 |
Why?
| Oligopeptides | 2 | 2013 | 95 | 0.380 |
Why?
| Osteoblasts | 4 | 2007 | 462 | 0.370 |
Why?
| Risk Factors | 18 | 2018 | 3724 | 0.370 |
Why?
| Hematopoietic Stem Cells | 2 | 2010 | 197 | 0.370 |
Why?
| Meta-Analysis as Topic | 2 | 2015 | 38 | 0.360 |
Why?
| Tumor Microenvironment | 3 | 2024 | 222 | 0.350 |
Why?
| Granulocyte Colony-Stimulating Factor | 2 | 2008 | 63 | 0.350 |
Why?
| Salvage Therapy | 9 | 2012 | 137 | 0.350 |
Why?
| Mice | 19 | 2024 | 5687 | 0.350 |
Why?
| Bone Marrow Transplantation | 5 | 2007 | 136 | 0.340 |
Why?
| Enzyme Inhibitors | 2 | 2019 | 377 | 0.340 |
Why?
| Membrane Proteins | 4 | 2017 | 332 | 0.340 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 4 | 2024 | 112 | 0.340 |
Why?
| Ultrasonography, Doppler | 2 | 2007 | 41 | 0.340 |
Why?
| Remission Induction | 10 | 2008 | 208 | 0.330 |
Why?
| Prospective Studies | 9 | 2019 | 2378 | 0.330 |
Why?
| Cell Cycle Proteins | 2 | 2021 | 161 | 0.330 |
Why?
| Neoplasm, Residual | 4 | 2022 | 160 | 0.330 |
Why?
| Myelodysplastic Syndromes | 4 | 2007 | 78 | 0.320 |
Why?
| B-Lymphocytes | 4 | 2021 | 171 | 0.320 |
Why?
| Waldenstrom Macroglobulinemia | 3 | 2018 | 40 | 0.310 |
Why?
| Lymphoma, B-Cell | 3 | 2021 | 49 | 0.310 |
Why?
| Immunosuppressive Agents | 3 | 2005 | 225 | 0.310 |
Why?
| Neovascularization, Pathologic | 1 | 2009 | 155 | 0.300 |
Why?
| Bone Neoplasms | 1 | 2010 | 179 | 0.300 |
Why?
| Killer Cells, Natural | 4 | 2024 | 106 | 0.290 |
Why?
| Brain Diseases, Metabolic | 1 | 2007 | 4 | 0.280 |
Why?
| Proteasome Endopeptidase Complex | 4 | 2018 | 116 | 0.280 |
Why?
| Chromosome Deletion | 3 | 2008 | 134 | 0.280 |
Why?
| Aged, 80 and over | 11 | 2019 | 3226 | 0.280 |
Why?
| Dose-Response Relationship, Drug | 6 | 2016 | 1372 | 0.280 |
Why?
| Hyperammonemia | 1 | 2007 | 22 | 0.280 |
Why?
| Amyloidosis | 2 | 2007 | 81 | 0.280 |
Why?
| Farnesyltranstransferase | 1 | 2006 | 5 | 0.280 |
Why?
| Research Design | 1 | 2009 | 353 | 0.280 |
Why?
| Thrombophilia | 4 | 2009 | 18 | 0.270 |
Why?
| Small Molecule Libraries | 2 | 2019 | 67 | 0.270 |
Why?
| Peripheral Blood Stem Cell Transplantation | 4 | 2014 | 56 | 0.270 |
Why?
| Hemostasis | 1 | 2007 | 59 | 0.270 |
Why?
| Bone and Bones | 1 | 2010 | 478 | 0.270 |
Why?
| Sirolimus | 1 | 2006 | 62 | 0.260 |
Why?
| Immunotherapy, Adoptive | 4 | 2024 | 163 | 0.260 |
Why?
| Gastrointestinal Neoplasms | 1 | 2006 | 40 | 0.260 |
Why?
| Cell Survival | 8 | 2018 | 589 | 0.260 |
Why?
| In Situ Hybridization, Fluorescence | 6 | 2016 | 231 | 0.250 |
Why?
| Caspases | 1 | 2006 | 103 | 0.250 |
Why?
| Flow Cytometry | 6 | 2018 | 474 | 0.250 |
Why?
| Diploidy | 2 | 2004 | 26 | 0.240 |
Why?
| beta 2-Microglobulin | 5 | 2008 | 39 | 0.240 |
Why?
| Antibody Formation | 1 | 2005 | 50 | 0.240 |
Why?
| Religion | 1 | 2005 | 62 | 0.240 |
Why?
| Activated Protein C Resistance | 4 | 2011 | 10 | 0.240 |
Why?
| Case-Control Studies | 10 | 2018 | 1156 | 0.230 |
Why?
| Aneuploidy | 1 | 2004 | 18 | 0.230 |
Why?
| Enoxaparin | 1 | 2004 | 31 | 0.230 |
Why?
| Ubiquitination | 2 | 2021 | 42 | 0.220 |
Why?
| Attitude to Health | 1 | 2005 | 193 | 0.220 |
Why?
| Adaptation, Psychological | 1 | 2005 | 227 | 0.220 |
Why?
| Osteolysis | 2 | 2022 | 74 | 0.220 |
Why?
| Multivariate Analysis | 5 | 2008 | 583 | 0.220 |
Why?
| Cancer Vaccines | 3 | 2010 | 80 | 0.210 |
Why?
| Cisplatin | 6 | 2009 | 286 | 0.210 |
Why?
| Cell Communication | 2 | 2006 | 68 | 0.210 |
Why?
| Pyrimidines | 3 | 2015 | 191 | 0.210 |
Why?
| Randomized Controlled Trials as Topic | 4 | 2012 | 573 | 0.210 |
Why?
| Blood Coagulation | 1 | 2003 | 60 | 0.210 |
Why?
| Mice, Inbred NOD | 6 | 2020 | 91 | 0.210 |
Why?
| Antigens, CD34 | 1 | 2003 | 75 | 0.210 |
Why?
| Critical Illness | 1 | 2005 | 302 | 0.210 |
Why?
| Cytogenetic Analysis | 6 | 2007 | 74 | 0.200 |
Why?
| Graft vs Host Disease | 5 | 2010 | 84 | 0.200 |
Why?
| Parathyroid Hormone | 3 | 2010 | 149 | 0.200 |
Why?
| STAT3 Transcription Factor | 4 | 2015 | 77 | 0.200 |
Why?
| Cyclophosphamide | 4 | 2003 | 168 | 0.200 |
Why?
| Leukemia, Myeloid | 1 | 2002 | 44 | 0.200 |
Why?
| Kidney | 1 | 2007 | 696 | 0.190 |
Why?
| Bone Resorption | 2 | 2022 | 302 | 0.190 |
Why?
| Chromosome Disorders | 1 | 2002 | 34 | 0.190 |
Why?
| Etoposide | 5 | 2009 | 77 | 0.190 |
Why?
| Time Factors | 9 | 2016 | 2935 | 0.190 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2015 | 67 | 0.190 |
Why?
| Hypothyroidism | 1 | 2002 | 56 | 0.190 |
Why?
| Logistic Models | 5 | 2018 | 900 | 0.190 |
Why?
| Chromosomes, Human, Pair 1 | 3 | 2006 | 92 | 0.180 |
Why?
| Antibodies, Bispecific | 1 | 2022 | 88 | 0.180 |
Why?
| Neoplasm Recurrence, Local | 4 | 2024 | 629 | 0.170 |
Why?
| Cytotoxicity, Immunologic | 3 | 2012 | 55 | 0.170 |
Why?
| Neoplasms | 2 | 2009 | 1251 | 0.170 |
Why?
| Xenograft Model Antitumor Assays | 5 | 2019 | 212 | 0.170 |
Why?
| DNA-Binding Proteins | 2 | 2020 | 418 | 0.170 |
Why?
| Glucuronidase | 2 | 2018 | 48 | 0.170 |
Why?
| Predictive Value of Tests | 5 | 2009 | 930 | 0.160 |
Why?
| Hematologic Neoplasms | 2 | 2016 | 99 | 0.160 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2013 | 128 | 0.160 |
Why?
| Cytokines | 4 | 2007 | 606 | 0.160 |
Why?
| Syndecan-1 | 3 | 2017 | 75 | 0.160 |
Why?
| Osteoclasts | 4 | 2022 | 427 | 0.160 |
Why?
| Kaplan-Meier Estimate | 6 | 2015 | 464 | 0.160 |
Why?
| Healthcare Disparities | 1 | 2022 | 281 | 0.160 |
Why?
| Hydrocarbons, Aromatic | 1 | 2018 | 2 | 0.160 |
Why?
| Solvents | 1 | 2018 | 29 | 0.150 |
Why?
| Pyridines | 1 | 2019 | 131 | 0.150 |
Why?
| Drug Tolerance | 1 | 2018 | 60 | 0.150 |
Why?
| T-Lymphocytes, Cytotoxic | 3 | 2010 | 63 | 0.150 |
Why?
| Jehovah's Witnesses | 1 | 2018 | 6 | 0.150 |
Why?
| Dendritic Cells | 3 | 2010 | 135 | 0.150 |
Why?
| Vincristine | 3 | 2003 | 82 | 0.150 |
Why?
| Cell Differentiation | 4 | 2022 | 640 | 0.150 |
Why?
| Platelet Count | 3 | 2008 | 65 | 0.150 |
Why?
| CDC2-CDC28 Kinases | 2 | 2015 | 11 | 0.150 |
Why?
| Risk Assessment | 5 | 2023 | 1270 | 0.140 |
Why?
| Iron | 2 | 2017 | 121 | 0.140 |
Why?
| Occupational Diseases | 1 | 2018 | 82 | 0.140 |
Why?
| Interleukin-6 | 2 | 2018 | 261 | 0.140 |
Why?
| Arsenicals | 2 | 2010 | 14 | 0.140 |
Why?
| Ascorbic Acid | 1 | 2017 | 21 | 0.140 |
Why?
| Pyruvate Kinase | 1 | 2017 | 7 | 0.140 |
Why?
| Oxides | 2 | 2010 | 18 | 0.140 |
Why?
| Drug Combinations | 1 | 2017 | 127 | 0.140 |
Why?
| Occupational Exposure | 1 | 2018 | 113 | 0.140 |
Why?
| Mice, SCID | 5 | 2018 | 178 | 0.140 |
Why?
| Anthropometry | 1 | 2017 | 95 | 0.140 |
Why?
| RNA Splicing | 1 | 2017 | 38 | 0.130 |
Why?
| Glycolysis | 1 | 2017 | 69 | 0.130 |
Why?
| Immunotherapy | 4 | 2006 | 235 | 0.130 |
Why?
| Transcription Factors | 1 | 2020 | 565 | 0.130 |
Why?
| Immunoglobulin lambda-Chains | 1 | 2016 | 14 | 0.130 |
Why?
| Factor V | 3 | 2011 | 11 | 0.130 |
Why?
| MicroRNAs | 1 | 2020 | 344 | 0.130 |
Why?
| Immunoglobulin kappa-Chains | 1 | 2016 | 20 | 0.130 |
Why?
| Fibrinolytic Agents | 2 | 2007 | 125 | 0.130 |
Why?
| Tumor Cells, Cultured | 6 | 2019 | 457 | 0.130 |
Why?
| Incidence | 3 | 2009 | 1032 | 0.130 |
Why?
| Leukocytes, Mononuclear | 2 | 2014 | 118 | 0.130 |
Why?
| Reproductive History | 1 | 2015 | 4 | 0.130 |
Why?
| Oncolytic Virotherapy | 1 | 2015 | 18 | 0.130 |
Why?
| Hormone Replacement Therapy | 1 | 2015 | 33 | 0.120 |
Why?
| Cyclopentanes | 1 | 2015 | 10 | 0.120 |
Why?
| Cell Adhesion Molecules | 1 | 2015 | 86 | 0.120 |
Why?
| Hemorrhage | 2 | 2007 | 197 | 0.120 |
Why?
| Ubiquitins | 1 | 2015 | 39 | 0.120 |
Why?
| Cation Transport Proteins | 1 | 2015 | 27 | 0.120 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 116 | 0.120 |
Why?
| NF-kappa B | 3 | 2018 | 315 | 0.120 |
Why?
| Aldehyde Dehydrogenase | 1 | 2014 | 25 | 0.120 |
Why?
| Postmenopause | 1 | 2015 | 96 | 0.120 |
Why?
| Drug Monitoring | 1 | 2015 | 79 | 0.120 |
Why?
| Intestines | 1 | 2016 | 172 | 0.120 |
Why?
| Leukapheresis | 1 | 2014 | 17 | 0.120 |
Why?
| Translocation, Genetic | 3 | 2005 | 240 | 0.120 |
Why?
| Protein-Tyrosine Kinases | 1 | 2015 | 88 | 0.110 |
Why?
| Transplantation Chimera | 3 | 2003 | 14 | 0.110 |
Why?
| Myeloma Proteins | 2 | 2020 | 26 | 0.110 |
Why?
| Gene Deletion | 3 | 2004 | 261 | 0.110 |
Why?
| Antibodies | 2 | 2024 | 153 | 0.110 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2016 | 475 | 0.110 |
Why?
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2013 | 24 | 0.110 |
Why?
| Veratrum Alkaloids | 1 | 2013 | 5 | 0.110 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 16 | 0.110 |
Why?
| Body Mass Index | 1 | 2017 | 677 | 0.110 |
Why?
| Isoxazoles | 1 | 2013 | 14 | 0.110 |
Why?
| Biopsy | 2 | 2006 | 588 | 0.110 |
Why?
| Hedgehog Proteins | 1 | 2013 | 32 | 0.110 |
Why?
| Sulfones | 1 | 2013 | 24 | 0.110 |
Why?
| Cystatin M | 2 | 2024 | 19 | 0.110 |
Why?
| Itraconazole | 1 | 2013 | 35 | 0.110 |
Why?
| Genetic Predisposition to Disease | 1 | 2016 | 511 | 0.110 |
Why?
| Metaphase | 3 | 2008 | 45 | 0.110 |
Why?
| Carrier Proteins | 2 | 2017 | 298 | 0.110 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 62 | 0.100 |
Why?
| Wnt Proteins | 1 | 2013 | 98 | 0.100 |
Why?
| B-Cell Maturation Antigen | 2 | 2024 | 99 | 0.100 |
Why?
| Renal Insufficiency | 3 | 2009 | 110 | 0.100 |
Why?
| Risk | 2 | 2011 | 324 | 0.100 |
Why?
| Infusions, Intravenous | 2 | 2003 | 213 | 0.100 |
Why?
| Viremia | 1 | 2012 | 22 | 0.100 |
Why?
| Chromosomes, Human, Pair 11 | 2 | 2002 | 49 | 0.100 |
Why?
| Drug Delivery Systems | 2 | 2005 | 143 | 0.100 |
Why?
| Cytomegalovirus Infections | 1 | 2012 | 38 | 0.100 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2012 | 45 | 0.100 |
Why?
| Radiopharmaceuticals | 2 | 2021 | 204 | 0.100 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2012 | 45 | 0.100 |
Why?
| Receptors, KIR | 2 | 2008 | 13 | 0.100 |
Why?
| Phosphorylation | 2 | 2020 | 525 | 0.100 |
Why?
| Fluorodeoxyglucose F18 | 2 | 2021 | 189 | 0.100 |
Why?
| Medical Oncology | 1 | 2012 | 98 | 0.090 |
Why?
| Alcohol Drinking | 1 | 2013 | 227 | 0.090 |
Why?
| Ligands | 2 | 2009 | 203 | 0.090 |
Why?
| Reoperation | 2 | 2004 | 460 | 0.090 |
Why?
| Inflammation | 1 | 2016 | 610 | 0.090 |
Why?
| Drug Evaluation, Preclinical | 1 | 2012 | 145 | 0.090 |
Why?
| Age Factors | 3 | 2005 | 1110 | 0.090 |
Why?
| Tretinoin | 2 | 2009 | 50 | 0.090 |
Why?
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 5 | 0.090 |
Why?
| Smoking | 1 | 2014 | 507 | 0.090 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 20 | 0.090 |
Why?
| Recombinant Proteins | 2 | 2010 | 476 | 0.090 |
Why?
| Janus Kinase 1 | 1 | 2010 | 16 | 0.090 |
Why?
| Antineoplastic Agents, Hormonal | 2 | 2007 | 49 | 0.090 |
Why?
| MAP Kinase Kinase 1 | 1 | 2010 | 23 | 0.090 |
Why?
| Down-Regulation | 2 | 2010 | 340 | 0.090 |
Why?
| Cyclin-Dependent Kinases | 1 | 2010 | 26 | 0.090 |
Why?
| Macrophages | 1 | 2013 | 364 | 0.090 |
Why?
| Authorship | 1 | 2010 | 12 | 0.080 |
Why?
| Neoplasm Staging | 3 | 2015 | 746 | 0.080 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 80 | 0.080 |
Why?
| Bone Density Conservation Agents | 1 | 2010 | 74 | 0.080 |
Why?
| Conflict of Interest | 1 | 2010 | 25 | 0.080 |
Why?
| Drug Industry | 1 | 2010 | 38 | 0.080 |
Why?
| Disclosure | 1 | 2010 | 39 | 0.080 |
Why?
| Diphosphonates | 1 | 2010 | 90 | 0.080 |
Why?
| Mice, Transgenic | 3 | 2021 | 540 | 0.080 |
Why?
| Chromosome Banding | 2 | 2006 | 18 | 0.080 |
Why?
| Leukocyte Count | 2 | 2014 | 69 | 0.080 |
Why?
| Plasmacytoma | 2 | 2011 | 42 | 0.080 |
Why?
| Periodicals as Topic | 1 | 2010 | 58 | 0.080 |
Why?
| Maximum Tolerated Dose | 2 | 2009 | 39 | 0.080 |
Why?
| Cell Cycle | 2 | 2010 | 226 | 0.080 |
Why?
| Oligonucleotide Array Sequence Analysis | 5 | 2014 | 405 | 0.080 |
Why?
| Magnetic Resonance Imaging | 3 | 2007 | 1548 | 0.080 |
Why?
| Cryoglobulinemia | 1 | 2008 | 13 | 0.080 |
Why?
| Blotting, Western | 3 | 2015 | 578 | 0.080 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2009 | 182 | 0.080 |
Why?
| Cytogenetics | 1 | 2008 | 21 | 0.080 |
Why?
| Prednisone | 2 | 2009 | 101 | 0.080 |
Why?
| Sulfonamides | 1 | 2009 | 126 | 0.070 |
Why?
| Polyethylene Glycols | 1 | 2008 | 86 | 0.070 |
Why?
| Pulmonary Embolism | 1 | 2009 | 99 | 0.070 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 572 | 0.070 |
Why?
| Neutrophils | 2 | 2014 | 145 | 0.070 |
Why?
| Immunophenotyping | 2 | 2007 | 105 | 0.070 |
Why?
| Hemoglobins | 1 | 2008 | 109 | 0.070 |
Why?
| Adoptive Transfer | 1 | 2007 | 30 | 0.070 |
Why?
| Heparin, Low-Molecular-Weight | 1 | 2007 | 21 | 0.070 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2024 | 125 | 0.070 |
Why?
| Histocompatibility Antigens Class I | 1 | 2007 | 46 | 0.070 |
Why?
| Phlebography | 1 | 2007 | 60 | 0.070 |
Why?
| Fibrinolysis | 1 | 2007 | 5 | 0.070 |
Why?
| Blood Coagulation Factors | 1 | 2007 | 17 | 0.070 |
Why?
| Ammonia | 1 | 2007 | 78 | 0.070 |
Why?
| Serum Albumin | 2 | 2008 | 57 | 0.070 |
Why?
| Chi-Square Distribution | 1 | 2007 | 277 | 0.070 |
Why?
| Biomedical Research | 1 | 2010 | 244 | 0.070 |
Why?
| Cell Membrane | 1 | 2007 | 246 | 0.070 |
Why?
| Brain | 2 | 2007 | 1319 | 0.070 |
Why?
| Drug Administration Schedule | 2 | 2006 | 370 | 0.070 |
Why?
| Osteoprotegerin | 1 | 2006 | 54 | 0.070 |
Why?
| Models, Genetic | 1 | 2006 | 172 | 0.070 |
Why?
| Guanosine | 1 | 2006 | 5 | 0.070 |
Why?
| Antibiotics, Antineoplastic | 1 | 2006 | 77 | 0.060 |
Why?
| Sex Factors | 3 | 2016 | 712 | 0.060 |
Why?
| Femur Head Necrosis | 1 | 2005 | 18 | 0.060 |
Why?
| Renal Dialysis | 1 | 2007 | 171 | 0.060 |
Why?
| Neovascularization, Physiologic | 1 | 2005 | 68 | 0.060 |
Why?
| Survivors | 1 | 2006 | 128 | 0.060 |
Why?
| Karyotyping | 1 | 2005 | 65 | 0.060 |
Why?
| Guanosine Triphosphate | 1 | 2004 | 18 | 0.060 |
Why?
| Gene Duplication | 1 | 2005 | 14 | 0.060 |
Why?
| Oncogene Proteins, Fusion | 1 | 2005 | 57 | 0.060 |
Why?
| Tissue Donors | 2 | 2003 | 121 | 0.060 |
Why?
| Kidney Transplantation | 1 | 2007 | 189 | 0.060 |
Why?
| Proteolysis | 2 | 2015 | 96 | 0.060 |
Why?
| Thrombophlebitis | 1 | 2004 | 24 | 0.060 |
Why?
| Genomic Instability | 1 | 2005 | 90 | 0.060 |
Why?
| Tomography, Emission-Computed | 1 | 2004 | 53 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 30 | 0.060 |
Why?
| RNA Interference | 2 | 2015 | 178 | 0.060 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.060 |
Why?
| X-Ray Microtomography | 1 | 2024 | 79 | 0.060 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2004 | 326 | 0.050 |
Why?
| Patient Selection | 1 | 2005 | 259 | 0.050 |
Why?
| Stem Cell Factor | 1 | 2003 | 7 | 0.050 |
Why?
| Discitis | 1 | 2003 | 11 | 0.050 |
Why?
| Confidence Intervals | 1 | 2003 | 154 | 0.050 |
Why?
| Neoplastic Cells, Circulating | 1 | 2004 | 74 | 0.050 |
Why?
| Probability | 1 | 2003 | 164 | 0.050 |
Why?
| Lymphocyte Transfusion | 1 | 2003 | 12 | 0.050 |
Why?
| Anxiety | 1 | 2005 | 285 | 0.050 |
Why?
| Interferons | 1 | 2002 | 38 | 0.050 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| Cell Count | 1 | 2003 | 150 | 0.050 |
Why?
| Cyclosporine | 1 | 2003 | 66 | 0.050 |
Why?
| Drug Therapy, Combination | 2 | 2017 | 384 | 0.050 |
Why?
| Geography | 1 | 2022 | 60 | 0.050 |
Why?
| Tacrolimus | 1 | 2003 | 53 | 0.050 |
Why?
| Thyroid Function Tests | 1 | 2002 | 25 | 0.050 |
Why?
| Blood Group Incompatibility | 1 | 2002 | 5 | 0.050 |
Why?
| Stromal Cells | 1 | 2002 | 75 | 0.050 |
Why?
| Administration, Oral | 1 | 2003 | 434 | 0.050 |
Why?
| ABO Blood-Group System | 1 | 2002 | 15 | 0.050 |
Why?
| Thyrotropin | 1 | 2002 | 49 | 0.050 |
Why?
| Leukemia, Promyelocytic, Acute | 1 | 2002 | 11 | 0.050 |
Why?
| Drug Interactions | 1 | 2002 | 206 | 0.050 |
Why?
| Fatal Outcome | 1 | 2002 | 197 | 0.050 |
Why?
| Cell Division | 1 | 2002 | 291 | 0.050 |
Why?
| Chromosome Mapping | 3 | 2006 | 153 | 0.050 |
Why?
| Genomics | 1 | 2023 | 279 | 0.050 |
Why?
| Graft Survival | 1 | 2002 | 159 | 0.050 |
Why?
| Cells, Cultured | 1 | 2005 | 1571 | 0.050 |
Why?
| Acute Disease | 1 | 2002 | 373 | 0.050 |
Why?
| RANK Ligand | 1 | 2022 | 187 | 0.050 |
Why?
| Cluster Analysis | 3 | 2006 | 219 | 0.040 |
Why?
| Young Adult | 3 | 2015 | 4102 | 0.040 |
Why?
| Tomography, X-Ray Computed | 1 | 2006 | 1164 | 0.040 |
Why?
| Depression | 1 | 2005 | 582 | 0.040 |
Why?
| Neoplasm Transplantation | 1 | 2020 | 86 | 0.040 |
Why?
| Odds Ratio | 2 | 2016 | 551 | 0.040 |
Why?
| Pain | 1 | 2003 | 387 | 0.040 |
Why?
| 3' Untranslated Regions | 1 | 2020 | 52 | 0.040 |
Why?
| Staphylococcal Infections | 1 | 2003 | 267 | 0.040 |
Why?
| Positron-Emission Tomography | 1 | 2021 | 292 | 0.040 |
Why?
| Postoperative Complications | 1 | 2007 | 1033 | 0.040 |
Why?
| Crystallography, X-Ray | 1 | 2019 | 147 | 0.040 |
Why?
| Antigens, CD | 2 | 2015 | 222 | 0.040 |
Why?
| Protein Conformation | 1 | 2019 | 162 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 248 | 0.040 |
Why?
| Mice, Inbred BALB C | 1 | 2019 | 296 | 0.040 |
Why?
| Coculture Techniques | 2 | 2012 | 142 | 0.040 |
Why?
| Bone Marrow Cells | 2 | 2015 | 196 | 0.040 |
Why?
| Receptors, Interleukin-6 | 1 | 2018 | 22 | 0.040 |
Why?
| Antigens, CD19 | 1 | 2018 | 29 | 0.040 |
Why?
| Microarray Analysis | 1 | 2018 | 70 | 0.040 |
Why?
| Drug Resistance | 1 | 2018 | 65 | 0.040 |
Why?
| Disease Management | 1 | 2020 | 178 | 0.040 |
Why?
| Interferon-gamma | 2 | 2010 | 177 | 0.040 |
Why?
| Protein Stability | 1 | 2018 | 43 | 0.040 |
Why?
| Gene Knockdown Techniques | 1 | 2018 | 105 | 0.040 |
Why?
| Epidemiologic Methods | 2 | 2008 | 46 | 0.040 |
Why?
| Aerobiosis | 1 | 2017 | 14 | 0.030 |
Why?
| Microfilament Proteins | 1 | 2017 | 42 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2022 | 1610 | 0.030 |
Why?
| HLA-A Antigens | 2 | 2007 | 10 | 0.030 |
Why?
| Thyroid Hormones | 1 | 2017 | 20 | 0.030 |
Why?
| Calcium-Binding Proteins | 1 | 2017 | 55 | 0.030 |
Why?
| Transplantation, Heterologous | 1 | 2017 | 75 | 0.030 |
Why?
| Polycomb Repressive Complex 1 | 1 | 2016 | 3 | 0.030 |
Why?
| Vaccination | 2 | 2010 | 280 | 0.030 |
Why?
| Transmembrane Activator and CAML Interactor Protein | 1 | 2016 | 6 | 0.030 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 50 | 0.030 |
Why?
| Genetic Loci | 1 | 2016 | 45 | 0.030 |
Why?
| Protein Binding | 1 | 2018 | 654 | 0.030 |
Why?
| Antibodies, Neoplasm | 2 | 2006 | 28 | 0.030 |
Why?
| Mice, Inbred ICR | 1 | 2016 | 23 | 0.030 |
Why?
| Mice, Knockout | 1 | 2018 | 844 | 0.030 |
Why?
| Microscopy, Electron, Transmission | 1 | 2015 | 75 | 0.030 |
Why?
| Reoviridae | 1 | 2015 | 25 | 0.030 |
Why?
| Genome-Wide Association Study | 1 | 2016 | 163 | 0.030 |
Why?
| Tumor Burden | 1 | 2016 | 130 | 0.030 |
Why?
| ras Proteins | 1 | 2015 | 64 | 0.030 |
Why?
| Repressor Proteins | 1 | 2016 | 148 | 0.030 |
Why?
| Receptors, Transferrin | 1 | 2015 | 16 | 0.030 |
Why?
| RNA, Messenger | 2 | 2010 | 1089 | 0.030 |
Why?
| Side-Population Cells | 1 | 2015 | 3 | 0.030 |
Why?
| Disease Models, Animal | 2 | 2013 | 1436 | 0.030 |
Why?
| Lentivirus | 1 | 2015 | 17 | 0.030 |
Why?
| Retinal Dehydrogenase | 1 | 2014 | 10 | 0.030 |
Why?
| Models, Biological | 1 | 2018 | 716 | 0.030 |
Why?
| Adenine | 1 | 2015 | 31 | 0.030 |
Why?
| Family | 1 | 2016 | 178 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2016 | 123 | 0.030 |
Why?
| Reactive Oxygen Species | 1 | 2017 | 409 | 0.030 |
Why?
| Cyclin B | 1 | 2014 | 4 | 0.030 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2014 | 9 | 0.030 |
Why?
| CDC2 Protein Kinase | 1 | 2014 | 16 | 0.030 |
Why?
| Portraits as Topic | 1 | 2014 | 2 | 0.030 |
Why?
| Cell Lineage | 1 | 2014 | 83 | 0.030 |
Why?
| Mitosis | 1 | 2014 | 88 | 0.030 |
Why?
| Drug Synergism | 1 | 2014 | 151 | 0.030 |
Why?
| beta Catenin | 1 | 2015 | 97 | 0.030 |
Why?
| Piperidines | 1 | 2015 | 99 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2014 | 131 | 0.030 |
Why?
| Pyrazoles | 1 | 2015 | 111 | 0.030 |
Why?
| Cell Movement | 1 | 2015 | 247 | 0.030 |
Why?
| Proportional Hazards Models | 2 | 2006 | 415 | 0.030 |
Why?
| Patient Safety | 1 | 2014 | 102 | 0.030 |
Why?
| Peptide Library | 1 | 2013 | 16 | 0.030 |
Why?
| Receptors, IgG | 1 | 2013 | 22 | 0.030 |
Why?
| Adolescent | 2 | 2014 | 6443 | 0.030 |
Why?
| Chromosomal Instability | 1 | 2013 | 16 | 0.030 |
Why?
| Epitopes | 1 | 2013 | 59 | 0.030 |
Why?
| Membrane Glycoproteins | 2 | 2006 | 245 | 0.030 |
Why?
| Protein Kinase Inhibitors | 1 | 2014 | 204 | 0.030 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 45 | 0.030 |
Why?
| Immunoglobulin M | 1 | 2012 | 58 | 0.020 |
Why?
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 8 | 0.020 |
Why?
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 9 | 0.020 |
Why?
| Cytomegalovirus | 1 | 2012 | 28 | 0.020 |
Why?
| Viral Load | 1 | 2012 | 76 | 0.020 |
Why?
| Peripheral Nervous System Diseases | 1 | 2012 | 58 | 0.020 |
Why?
| Interleukin-2 | 1 | 2012 | 71 | 0.020 |
Why?
| Virus Activation | 1 | 2012 | 37 | 0.020 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 137 | 0.020 |
Why?
| Arkansas | 2 | 2008 | 1985 | 0.020 |
Why?
| Viper Venoms | 1 | 2011 | 7 | 0.020 |
Why?
| Asymptomatic Diseases | 1 | 2011 | 37 | 0.020 |
Why?
| Lymphocyte Activation | 1 | 2012 | 164 | 0.020 |
Why?
| Protein C | 1 | 2011 | 18 | 0.020 |
Why?
| Neoadjuvant Therapy | 1 | 2012 | 120 | 0.020 |
Why?
| Chemotherapy, Adjuvant | 1 | 2011 | 121 | 0.020 |
Why?
| Interferon Regulatory Factor-1 | 1 | 2010 | 14 | 0.020 |
Why?
| Cell Growth Processes | 1 | 2010 | 22 | 0.020 |
Why?
| Antiviral Agents | 1 | 2012 | 170 | 0.020 |
Why?
| Immunoglobulin Idiotypes | 1 | 2010 | 5 | 0.020 |
Why?
| CD40 Ligand | 1 | 2010 | 14 | 0.020 |
Why?
| Hypersensitivity, Delayed | 1 | 2010 | 19 | 0.020 |
Why?
| Interleukin-4 | 1 | 2010 | 42 | 0.020 |
Why?
| Immunity, Cellular | 1 | 2010 | 63 | 0.020 |
Why?
| Adjuvants, Immunologic | 1 | 2010 | 51 | 0.020 |
Why?
| Diagnosis, Differential | 2 | 2004 | 1033 | 0.020 |
Why?
| Mutation | 1 | 2015 | 1280 | 0.020 |
Why?
| Physician's Role | 1 | 2010 | 48 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2010 | 208 | 0.020 |
Why?
| Education, Medical, Continuing | 1 | 2010 | 71 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2012 | 468 | 0.020 |
Why?
| Hyperhomocysteinemia | 1 | 2009 | 30 | 0.020 |
Why?
| Protein Isoforms | 1 | 2009 | 116 | 0.020 |
Why?
| Indazoles | 1 | 2009 | 46 | 0.020 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 27 | 0.020 |
Why?
| Safety | 1 | 2009 | 77 | 0.020 |
Why?
| Algorithms | 1 | 2012 | 625 | 0.020 |
Why?
| Vasculitis | 1 | 2008 | 29 | 0.020 |
Why?
| Haplotypes | 1 | 2008 | 84 | 0.020 |
Why?
| Ploidies | 1 | 2008 | 11 | 0.020 |
Why?
| Twins | 1 | 2007 | 20 | 0.020 |
Why?
| Double-Blind Method | 1 | 2009 | 708 | 0.020 |
Why?
| Age Distribution | 1 | 2007 | 170 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2008 | 144 | 0.020 |
Why?
| Creatinine | 1 | 2007 | 145 | 0.020 |
Why?
| Multigene Family | 1 | 2006 | 54 | 0.020 |
Why?
| Blood Proteins | 1 | 2007 | 84 | 0.020 |
Why?
| Partial Thromboplastin Time | 1 | 2006 | 12 | 0.020 |
Why?
| Cyclin D | 1 | 2006 | 18 | 0.020 |
Why?
| Syndecans | 1 | 2006 | 37 | 0.020 |
Why?
| Heterozygote | 1 | 2006 | 83 | 0.020 |
Why?
| Cyclins | 1 | 2006 | 38 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2006 | 43 | 0.020 |
Why?
| Proteoglycans | 1 | 2006 | 83 | 0.020 |
Why?
| Amiloride | 1 | 2005 | 8 | 0.020 |
Why?
| HLA-A2 Antigen | 1 | 2005 | 11 | 0.020 |
Why?
| Cell Line | 1 | 2008 | 988 | 0.020 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2007 | 181 | 0.020 |
Why?
| Transduction, Genetic | 1 | 2005 | 46 | 0.020 |
Why?
| Radiography | 1 | 2007 | 485 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2006 | 162 | 0.020 |
Why?
| Neoplasms, Experimental | 1 | 2006 | 110 | 0.020 |
Why?
| Interferon-alpha | 1 | 2005 | 47 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2007 | 859 | 0.020 |
Why?
| Monocytes | 1 | 2005 | 127 | 0.010 |
Why?
| Databases, Factual | 1 | 2007 | 673 | 0.010 |
Why?
| Clone Cells | 1 | 2004 | 70 | 0.010 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 226 | 0.010 |
Why?
| Monosomy | 1 | 2003 | 5 | 0.010 |
Why?
| Fibroblasts | 1 | 2005 | 336 | 0.010 |
Why?
| Trisomy | 1 | 2003 | 27 | 0.010 |
Why?
| History, 21st Century | 1 | 2003 | 56 | 0.010 |
Why?
| History, 20th Century | 1 | 2003 | 100 | 0.010 |
Why?
| Interphase | 1 | 2003 | 9 | 0.010 |
Why?
| Plasmapheresis | 1 | 2003 | 11 | 0.010 |
Why?
| Back Pain | 1 | 2003 | 38 | 0.010 |
Why?
| United States | 1 | 2013 | 4955 | 0.010 |
Why?
| Pore Forming Cytotoxic Proteins | 1 | 2002 | 9 | 0.010 |
Why?
| Perforin | 1 | 2002 | 11 | 0.010 |
Why?
| Anemia | 1 | 2003 | 67 | 0.010 |
Why?
| Cohort Studies | 1 | 2006 | 1452 | 0.010 |
Why?
| Antigen Presentation | 1 | 2002 | 25 | 0.010 |
Why?
| Red-Cell Aplasia, Pure | 1 | 2002 | 7 | 0.010 |
Why?
| Prevalence | 1 | 2005 | 971 | 0.010 |
Why?
| Quality Assurance, Health Care | 1 | 2003 | 150 | 0.010 |
Why?
| Erythrocyte Transfusion | 1 | 2002 | 52 | 0.010 |
Why?
| Cell Culture Techniques | 1 | 2002 | 96 | 0.010 |
Why?
| DNA, Neoplasm | 1 | 2002 | 143 | 0.010 |
Why?
| Graft Rejection | 1 | 2002 | 172 | 0.010 |
Why?
| Kidney Diseases | 1 | 2003 | 213 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2003 | 745 | 0.010 |
Why?
|
|
Tricot's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|